He remained free from palpitations, fainting, or syncopal episodes over the next fourteen months without quinidine
The formulation of dextromethorphan and quinidine
used in the study already has Food and Drug Administration marketing approval with the brand name Nuedexta for treating pseudobulbar affect (PBA), which can occur in patients with, for example, amyotrophic lateral sclerosis or multiple sclerosis.
The 93 patients randomized to the investigational treatment started on 20 mg dextromethorphan and 10 mg quinidine
administered orally once daily for a week, followed by an up-titration schedule over 2 weeks to reach 30 mg dextromethorphan twice daily plus 10 mg quinidine
twice daily, the dosage they continued for an additional 7 weeks.
[sup] More solid evidence in support of J wave syndromes as repolarization abnormalities is the inhibitory effect of quinidine
on both I [sub]Na and I [sub]to .
concentrations ranged from 2.06 nM to 500 nM.
The CDC-recommended treatment, parenteral quinidine
(given with a second drug: doxycycline, tetracycline, or clindamycin), is the only Federal Drug Administration (FDA)--approved parenteral antimalarial regimen currently available in the United States.
Intravenous (IV) quinine (a 4-quinoline methanol) has been the mainstay of treatment for severe falciparum malaria, although in some countries, including the United States, quinidine
, the dextrorotatory diastereoisomer of quinine, is 2 used because of the non-availability of IV quinine .
is the drug of first choice in the management of atrial flutters/fibrillations, a sizeable number of dogs did not responded well to quinidine
and therefore were switched to digoxin and most of the dogs responded well except 13 dogs.
Cardiovascular drugs: Amiodarone, Apixaban, Clopidogrel, Dronedarone, Eplerenone, Felodipine, Nifedipine, Quinidine
, Rivaroxaban, Ticagrelor
Avanir's NUEDEXTA (dextromethorphan HBr and quinidine
sulfate) has been cleared by the US Food and Drug Administration (FDA) for the treatment of pseudobulbar affect.
Among the tanshinones, only dihydrotanshinone significantly inhibited CYP2D6 activity ([IC.sub.50]= 35.4 [micro]M), compared to quinidine
, a specific CYP2D6 inhibitor ([IC.sub.50] = 0.9 [micro]M).
In light of these considerations, he was diagnosed as having idiopathic short QT intervals rather than SQTS and has not yet been treated with pharmacological therapy, such as quinidine
, or an implantable cardioverter-defibrillator (ICD).